Warfarin pharmacogenetics: to genotype or not to genotype, that is the question

L H Cavallari; E A Nutescu

doi:10.1038/clpt.2014.78

Warfarin pharmacogenetics: to genotype or not to genotype, that is the question

Clin Pharmacol Ther. 2014 Jul;96(1):22-4. doi: 10.1038/clpt.2014.78.

Authors

L H Cavallari¹, E A Nutescu²

Affiliations

¹ Department of Pharmacotherapy and Translational Research, University of Florida, Gainesville, Florida, USA.
² 1] Department of Pharmacotherapy and Translational Research, University of Florida, Gainesville, Florida, USA [2] Department of Pharmacy Systems, Outcomes, and Policy, University of Illinois at Chicago, Chicago, Illinois, USA [3] Center for Pharmacoepidemiology and Pharmacoeconomic Research, University of Illinois at Chicago, Chicago, Illinois, USA.

PMID: 24942399
DOI: 10.1038/clpt.2014.78

Abstract

Genotype is well recognized to influence the dose of warfarin necessary for therapeutic anticoagulation. Recent randomized controlled trials evaluating the clinical utility of genotype-guided warfarin dosing have produced varying results. We review the design and results of the recent clinical trials, assess the impact of their findings on warfarin dosing, and examine unanswered questions related to clinical implementation of warfarin pharmacogenetics.

Publication types

Research Support, N.I.H., Extramural
Review

MeSH terms

Anticoagulants / administration & dosage*
Anticoagulants / pharmacokinetics
Aryl Hydrocarbon Hydroxylases / genetics
Clinical Trials as Topic
Cytochrome P-450 CYP2C9
Genotype
Humans
Pharmacogenetics
Racial Groups
Vitamin K Epoxide Reductases / genetics
Warfarin / administration & dosage*
Warfarin / pharmacokinetics

Substances

Anticoagulants
Warfarin
CYP2C9 protein, human
Cytochrome P-450 CYP2C9
Aryl Hydrocarbon Hydroxylases
VKORC1 protein, human
Vitamin K Epoxide Reductases

Grants and funding

K23HL112908/HL/NHLBI NIH HHS/United States